While our study attempts to more broadly enrich for AIPC based on predefined criteria for NEPC, DNPC, and AVPC as opposed to selecting tumors solely based on AR expression, we found a similar prevalence of androgen-indifferent tumors (12%) among primary prostate cancer samples analyzed in the ORIEN database. This evidence concerns the gene AR and prostate cancer.